Exploiting directed evolution for the discovery of biologicals

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 2, 2006, Pages 269-275

  Douthwaite, Julie ^a   Jermutus, Lutz ^a  

^a MEDIMMUNE LTD   (United Kingdom)

Author keywords

Affinity; Hot spots; In vitro evolution; Protein therapeutics; Ribosome display; Stability

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CAT 354; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY INTERLEUKIN 13; MOTAVIZUMAB; NUMAX; RANIBIZUMAB; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; DNA LIBRARY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; NONHUMAN; POLYMERASE CHAIN REACTION; RECOMBINANT DNA TECHNOLOGY; REVIEW; RIBOSOME;

ANIMALS; DIRECTED MOLECULAR EVOLUTION; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; PROTEINS;

EID: 33645024046     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Walsh G: Biopharmaceutical benchmarks - 2003. Nat Biotechnol (2003) 21(8):865-870.
2. Goldberg J, Jin Q, Ambroise Y, Satoh S, Desharnais J, Capps K, Boger DL: Erythropoietin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc (2002) 124(4):544-555.
3. Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, Valoret EI, Duffy KJ, Luengo JL, Rosen J, Miller SG et al: Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol (2005) 33(1):85-93.
4. Reichert JM, Paquette C: Clinical development of therapeutic recombinant proteins. Biotechniques (2003) 35(1):176-178.
5. Reichert JM, Paquette C: Therapeutic recombinant proteins: Trends in US approvals 1982 to 2002. Curr Opin Mol Ther (2003) 5(2):139-147.
6. Gomez-Perez FJ, Rull JA: Insulin therapy: Current alternatives. Arch Med Res (2005) 36(3):258-272.
7. Nicola NA: Hemopoietic cell growth factors and their receptors. Annu Rev Biochem (1989) 58:45-77.
8. Park S, Yang X, Saven JG: Advances in computational protein design. Curr Opin Struct Biol (2004) 14(4):487-494.
9. Hoogenboom HR: Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 23(9):1105-1116. Provides a detailed review of display technologies, antibody library types and selection strategies, and presents the details of some current recombinant library-derived therapeutic mAbs.
10. Schmitz U, Versmold A, Kaufmann P, Frank HG: Phage display: A molecular tool for the generation of antibodies - A review. Placenta (2000) 21(Suppl A):S106-S112.
11. Lipovsek D, Plückthun A: In vitro protein evolution by ribosome display and mRNA display. J Immunol Methods (2004) 290(1-2):51-67.
12. Zahnd C, Spinelli S, Luginbuhl B, Amstutz P, Cambillau C, Plückthun A: Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem (2004) 279(18):18870-18877.
13. HH by mutational hotspot randomization. J Immunol Methods (2005) 297(1-2):213-224.
14. Ho M, Kreitman RJ, Onda M, Pastan I: In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem (2005) 280(1):607-617.
15. Thom G, Cockroft AC, Buchanan AG, Candotti CJ, Cohen ES, Lowne D, Monk P, Shorrock-Hart CP, Jermutus L, Minter RR: Probing a protein-protein interaction by in vitro evolution. (2006): manuscript submitted.
16. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR: Rational design and engineering of therapeutic proteins. Drug Disc Today (2003) 8(5):212-221. Provides a comprehensive review of the engineering of biologicals.
17. Wunderlich M, Martin A, Staab CA, Schmid FX: Evolutionary protein stabilization in comparison with computational design. J Mol Biol (2005) 361(5):1160-1168.
18. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W: Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon α2b. Pharm Res (2005) 22(12):1997-2006. Provides an excellent example of the importance of protein aggregation as a T-cell epitope-independent trigger for immunogenicity.
19. Jermutus L, Honegger A, Schwesinger F, Hanes J, Plückthun A: Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci USA (2001) 98(1):75-80.